Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-30

Chemogenomic profiling of drug-protein binding by shape, enthalpy/entropy and interaction kinetics

Obiettivo

Once a new drug target is discovered, screening techniques are applied to detect prospective hits. However, which hit should be taken to the next level of development? This decision is most crucial as it entails huge financial commitments of the subsequent drug optimization. In consequence drugs are only developed against diseases that promise short-term profit. Chemogenomic profiling allows to compile parameters characterizing binding of drug candidates that achieve optimal interference with protein function. Membrane proteins demand different properties than viral ones. Either high isoform selectivity, promiscuous family-wide binding or efficient resistance tolerance is desired. This calls for very different ligand binding characteristics, requiring either enthalpy-/entropy-driven binding, rigid shape complementarity or pronounced residual mobility at the binding site. Interaction kinetics determine on/off-rates and the time a drug spends with its target. Their correct adjustment is essential for drug efficacy. At present chemogenomic binding parameters are rarely available and their correlation with the required target properties is hardly understood. We want to compile a knowledge base from congeneric protein-ligand series to correlate structural, thermodynamic, interaction-kinetic and dynamic behaviour to predict the qualities a lead must meet to optimally address a target. Our studies involve crystal structure analyses, microcalorimetry, molecular dynamics simulations, site-directed mutagenesis and interaction kinetics. This provides a comprehensive picture to productively change our current understanding of drug-protein binding to move from a current trial-and-error to a more efficient rational approach. It provides the opportunity to also consider orphan drugs and address neglected diseases.

Invito a presentare proposte

ERC-2010-AdG_20100317
Vedi altri progetti per questo bando

Meccanismo di finanziamento

ERC-AG - ERC Advanced Grant

Istituzione ospitante

PHILIPPS UNIVERSITAET MARBURG
Contributo UE
€ 1 754 615,28
Indirizzo
BIEGENSTRASSE 10
35037 Marburg
Germania

Mostra sulla mappa

Regione
Hessen Gießen Marburg-Biedenkopf
Tipo di attività
Higher or Secondary Education Establishments
Ricercatore principale
Gerhard Friedrich Klebe (Prof.)
Contatto amministrativo
Lois Woestman (Dr.)
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)